

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Arthur Lander et al.

Serial No: 09/807,575

Filed: July 12, 2001

For: GLYPICANS FOR THE DETECTION AND  
TREATMENT OF HUMAN CARCINOMA

Art Unit: Not Assigned

Examiner: Not Assigned

**AMENDMENT**

Box PCT

Commissioner for Patents  
Washington, D.C. 20231

I hereby certify that this correspondence  
is being deposited with the United States  
Postal Service with sufficient postage as  
first class mail in an envelope addressed  
to:

Commissioner for Patents  
Washington D.C. 20231, on

October 17, 2001

Date of Deposit

Kathleen Dunn

Name

  
Signature

Dear Sir:

In response to the "Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US)" and in response to "Notification to Comply with Requirements for Patent Application Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" dated September 14, 2001, response to which is due November 14, 2001, the Examiner is requested to enter the following amendment and consider the following remarks:

**IN THE SPECIFICATION:**

Kindly enter the attached "Sequence Listing" into the specification of the above referenced application and delete any "Sequence Listing" that may already exist within the specification.

**REMARKS**

A correct CRF diskette and a paper version of the "Sequence Listing" are provided herewith. Applicants hereby state that the contents of the CRF diskette and the paper version of the CRF are identical. No new matter has been added.